Q3 2024 saw 9.1% revenue growth, margin expansion, and strong EBITDA, driven by higher average ticket and complex surgeries. SulAmérica improved its loss ratio and beneficiary base, while new hospital expansions and disciplined capital allocation support a positive 2025 outlook.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.